News | February 02, 2022
Panacea Biotec sells its domestic formulations business to Mankind Pharma
The pharma division’s domestic business generated turnover of Rs. 219.85 crore for the last financial year
The pharma division’s domestic business generated turnover of Rs. 219.85 crore for the last financial year
It will enable the company to branch out to new geographies and strengthen its presence in South Africa
The acquisition of myPOLS Biotec complements Medix Biochemica’s leading portfolio of IVD raw materials and expands its reagent offerings for molecular diagnostics
The CAS SciFinder Discovery Platform expansion unlocks human-indexed insights from journals and patents in over 50 languages dating back to 1957 and 70 million biosequences curated by CAS scientists
Intranasal vaccines are easier to administer in mass immunisation campaigns and help reduce or stop transmission
Company to manufacture drug substance for clinical supply of HaemaLogiX’s lead multiple myeloma drug candidate, KappaMab, at its new state-of-the-art facility in Guangzhou, China
The companies will continue with their exclusive agreements, including commercialization of their current portfolio
First participants enrolled in clinical trial received Omicron-based vaccine candidate as a two-dose primary series and as a booster dose
Pfizer is evaluating the FDA’s comments and will work with the agency to determine an appropriate path forward
Go-ahead for pivotal clinical trial which is expected to commence by March
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
